Crystec are delighted to have been shortlisted for the RSC Emerging Technologies Competition, which is focused on accelerating the commercialisation of innovative technologies. Crystec will pitch their novel treatment for urge incontinence to a panel of experts at Chemistry Means Business in Manchester 13th - 14th June 2017.
Crystec are honoured to have been shortlisted for the RSC Emerging Technologies Competition. The Competition aims to accelerate the commercialisation of innovative technologies by bringing together entrepreneurs, organisations and experts to provide support for the progression of genuinely novel chemistry-related inventions.
Crystec were shortlisted for their innovative, on-demand treatment for urge incontinence. Urge urinary incontinence affects more than 200 million people worldwide. Current oral treatments incur considerable side effects, in part due to maintaining high, sustained levels of medication. The Crystec team have applied their supercritical fluid (SCF) technology to engineer an inhalable formulation of an existing anticholinergic medicine, enabling rapid onset and offset, and episodic treatment, reducing the overall dose and limiting adverse effects. This will be the first on-demand treatment for urge incontinence and has the potential to transform how the condition is managed.
Crystec will have the opportunity to pitch their invention to a panel of experts during Chemistry Means Business in Manchester (13th - 14th June 2017). For more information about the competition and other shortlisted candidates, visit http://www.rsc.org/competitions/emerging-technologies/.